Video

Safety Profile of S1P Receptor Modulators for Multiple Sclerosis

Author(s):

Krzysztof Selmaj, MD, PhD

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!
Related Videos
Gabrielle Macaron, MD
Agne Straukiene, MD
Cassandra Moore, MPH, CPH
Sam Hooshmand, DO
Sumaira Ahmed
Related Content
Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
June 25th 2025

Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Marco Meglio
Episode 142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients
May 30th 2025

Episode 142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients

Marco Meglio Taylor Hess, MD
NeurologyLive® Friday 5 — June 20, 2025
June 20th 2025

NeurologyLive® Friday 5 — June 20, 2025

NeurologyLive® Staff
Neurology Unwrapped: 2024’s Most Intriguing Conversations
December 27th 2024

Neurology Unwrapped: 2024’s Most Intriguing Conversations

Marco Meglio
NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs
June 18th 2025

NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs

Tiffany Malone, MSW, MSCS Isabella Ciccone, MPH
Phase 2B ExTINGUISH Trial Aims to Assess Efficacy of Inebilizumab for NMDAR Encephalitis
June 17th 2025

Phase 2B ExTINGUISH Trial Aims to Assess Efficacy of Inebilizumab for NMDAR Encephalitis

Abigail Lewis
© 2025 MJH Life Sciences

All rights reserved.